• CardioExcyte 96

    インピーダンス&細胞外電位のハイブリッド測定
  • CardioExcyte 96

    心臓安全性スクリーニングに最適
  • CardioExcyte 96

    ラベルフリー:次世代の細胞解析
  • CardioExcyte 96

    直感的にデータ解析可能 & 不整脈の検出

2018 - HTS Phase I study: an update on progress of the CiPA Ion Channel Work Stream using the SyncroPatch 384PE and Patchliner

icon sp96  SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i),   icon pl   Patchliner and   Icon CE   CardioExcyte 96 Oral Presentation

Presenter: 
Tim Strassmaier, Nanion Technologies Inc. USA
Source:
Webinar: "CiPA study: Bridging ion channel and myocyte data", September 12, 2018

Title:
CiPA myocyte phase II validation study results: cross-site comparison using the CardioExcyte 96

Abstract:

The CiPA HTS Ion Channel Working Group finalized its phase I study in 2017. Amongst other external sites, Nanion Technologies in Germany, USA and Japan participated with the Patchliner and the SyncroPatch 384PE in this study. A comparative view of the ion channel targets and a cross-platform and cross-site comparison will be presented. Furthermore, results from the myocyte Work Stream using arrhythmogenic compounds will be compared and confirmed with patch clamp data derived from the HTS Work Stream.

Please note: The original webinar presentation contained 8 slides with data of an upcoming publication. Due to confidentiality reasons, the relevant slides were cut out of the movie. 

Back

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.